Sinovent
Latest round
- Series E
Last raised
- Feb 2024
Total raised
- $243M
Investors
- 18
About Sinovent
Founded in 2017 and based in Suzhou, China, Sinovent operates as a biopharmaceuticals firm that offers small molecule drug research and development services. The company has set up branch offices in Boston, Beijing, Shanghai, and Sydney. There are 252 employees in the company. Sinovent has developed a pipeline of innovative drugs such as BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and new-generation ADCs, utilizing its own technology platforms of targeted therapies, anti-infectives, and PROTACs. XNW4107 is a ß-lactamase broad-spectrum anti-drug-resistant bacterial drug with antimicrobial efficacy against Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), and carbapenem antibiotic-resistant Enterobacteriaceae (CRE). EZH2 inhibitor XNW5004 can be used to treat blood cancer and prostate cancer. And XNW3009 is a uric acid-lowering drug. The company’s revenue is generated by providing drugs for treating diseases such as tumors, anti-infections and metabolism. The company will continue to improve the technology platforms of targeted therapy, anti-infection and PROTAC, and accelerate the operation of production bases as well as the construction of commercialization teams.
Who invested in Sinovent
18 investors across 4 rounds
See all investors in Sinovent
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sinovent
Who invested in Sinovent?
Sinovent has 18 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sinovent raised?
Sinovent has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Sinovent last raise money?
Sinovent's most recent round on record is a Series E, in Feb 2024.
What does Sinovent do?
Founded in 2017 and based in Suzhou, China, Sinovent operates as a biopharmaceuticals firm that offers small molecule drug research and development services.
Where is Sinovent headquartered?
Sinovent is headquartered in Suzhou, China.
Which VCs invest in companies like Sinovent?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Sinovent's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Sinovent? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.